Astelin

Trade name and formulation: RoundupTM , Roundup UltraTM Average use rate: 0.55 Ib a.i. A Number of application: 1.5 Percent acres treated: 10% Amount applied per year: 189, 900 Ib Application time: preplant; applied to Roundup Ready Corn only at the growing stages from emergence through the V-6 stage six leaf collars visible ; or until plant is 24 inches tall; prior to corn harvest and after corn is physiologically matured; before corn silks and at stage of weed growth recommended on the label Target plants: annual and perennial broadleaf weeds in field corn, sweet corn, and popcorn Component of other products: Fieldmaster, LandmasterBW Comments: not applied directly to water or to areas where water is present. Do not harvest or feed treated vegetation for 8 weeks following application. The populations assigned to the two pharmacy types are generally similar in personal demographics and in the length of baseline and follow-up periods, although the size of the study groups leads to statistical significance for small differences. Likewise there are small but significant differences in the observed rate of several of the chronic disease diagnosis categories. GI ulcer and hemorrhage diagnoses and treatments do not vary significantly between the two study groups. The one significant deviation of interest is the frequency of concurrence between an NSAID prescription fill and the reporting of an ulcer or GI hemorrhage diagnosis is elevated in the control group during the baseline period. Regression Results In total five models were prepared for the main population and two risk groups, resulting in ten regression analyses. The parameter estimates for all variables used in the logistic regression of the main population are included in Appendix F. The demographic and clinical covariates generally showed the anticipated relationship to GI outcomes. Three factors that consistently showed a non-significant relationship to any GI outcomes were withdrawn from the models, they were: 1 ; exposure to an anticoagulant medication or an coagulation disorder diagnosis in the baseline period; 2 ; the drugs grouped under CRD2; 3 ; the diagnoses grouped under GI3. Below are presented the adjusted odds ratios derived from the covariance matrix for each model in the general population and two of the risk groups. The main covariate influences were observation time, longer follow-up leads to greater risk, increased age is correlated with greater risk of GI outcomes, gender, female reduces risk and a baseline GI diagnosis is highly associated with the occurrence of events in the study period. Baseline diagnoses of renal failure, anemia, alcoholism were all strongly correlated with GI bleed hospitalizations.

Antihistamines: -Astemizole Hismanal ; : 6-12 yr: 5 mg day PO qd 12 yr: 10 mg PO qd [tab: 10 mg]. -Loratadine Claritin ; 3 yrs and 30 kg: 5 mg PO qd 30 kg: 10 mg PO qd. [syrup: 1mg ml; tab: 10 mg; tab, rapidly disintegrating: 10 mg] -Cetirizine Zyrtec ; 12 y: 5-10 mg qd 6-11 y: 5-10 mg qd [tabs: 5, 10 mg Syrup: 5 mg 5 ml] -Fexofenadine Allegra ; , 12 y: 60 mg bid [60 mg] -Actifed [per cap or tab or 10 ml syrup: triprolidine 2.5 mg, pseudoephedrine 60 mg] 4 mg pseudoephedrine kg day PO tid-qid OR 4 m-2 yr: 1.25 ml PO q6-8h 2-4 yr: 2.5 ml PO q6-8h 4-6 yr: 3.75 ml PO q6-8h 6-11y: 5 ml or tab PO q6-8h 12 yr: 10 ml or 1 cap tab PO q6-8h. -Chlorpheniramine maleate Chlor-Trimeton ; : 0.35 mg kg day PO q4-6h OR 2-5 yr: 1 mg PO q4-6h max 4 mg day ; 6-11y: 2 mg PO q4-6h max 12 mg day ; 12y: 4 mg PO q4-6h or 8-12 mg SR q8-12h max 24 mg day ; . [cap, SR: 8, 12 mg; soln: 2 mg 5 ml; tab: 4, 8, 12 mg; tab, chew: 2 mg; tab, SR: 8, 12 mg] -Diphenhydramine Benadryl ; 1 mg kg dose PO q6h prn, max 50 mg dose [elixir liquid: 12.5 mg 5 ml; tab, cap: 25, 50 mg]. Intranasal Therapy: -Azelastine Astelib ; 3-12 yr: 1 spray in each nostril bid 12 yr: 2 sprays in each nostril bid [nasal soln: 1 mg ml, 17 ml 137 mcg spray ; ] -Beclomethasone Beconase, Vancenase ; 6-11 yrs: 1 spray into each nostril tid 12 yrs: 1 spray into each nostril bid-qid [42 mcg actuation] -Beclomethasone aqueous Beconase AQ ; 6-11 yrs: 1-2 sprays into each nostril bid 12 yrs: 1-2 sprays into each nostril bid [42 mcg actuation] -Beclomethasone Double Strength Vancenase AQ ; 6-11 yrs: 1-2 puffs into each nostril qd 12 yrs: 1-2 sprays into each nostril qd [84 mcg actuation] -Budesonide Rhinocort ; 6-11 yrs: 2 sprays into each nostril bid or 4 sprays into each nostril qAM 12 yrs: 2 sprays into each nostril bid or 4 sprays into each nostril qAM [32 mcg actuation] -Budesonide aqueous Rhinocort AQ ; 6-11 yrs: 1-2 sprays into each nostril bid 12 yrs: 1 sprays into each nostril qd, may increase up to 4 sprays into each nostril qAM [32 mcg actuation] -Cromolyn Nasalcrom ; 1 puff into each nostril q3-4h [40 mg ml 13 ml]. -Flunisolide Nasalide, Nasarel ; 6-11 yrs: 1 spray into each nostril tid or 2 sprays into each nostril bid 12 yrs: 2 sprays into each nostril bid-tid [25 mcg actuation]. -Fluticasone Flonase. DESCRIPTION Astrlin azelastine hydrochloride ; Nasal Spray, 137 micrograms mcg ; , is an antihistamine formulated as a metered-spray solution for intranasal administration. Azelastine hydrochloride occurs as a white, almost odorless, crystalline powder with a bitter taste. It has a molecular weight of 418.37. It is sparingly soluble in water, methanol, and propylene glycol and slightly soluble in ethanol, octanol, and glycerine. It has a melting point of about 225C and the pH of a saturated solution is between 5.0 and 5.4. Its chemical name is ; -1- 2H ; -phthalazinone, 4-[ 4-chlorophenyl ; methyl]-2 hexahydro-1-methyl-1H-azepin-4-yl ; -, monohydrochloride. Its molecular formula is C 22 CIN 3 OHCl with the following chemical structure.

Table of Contents ITEM 7--MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and the related notes and other financial information included elsewhere in this Annual Report on Form 10-K. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report on Form 10-K, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. You should review the section entitled "Risk Factors" of this Annual Report on Form 10-K for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. Overview We are a biopharmaceutical company focused on the discovery, development and commercialization of novel orally-administered small molecule drugs that modulate ion channel targets. Utilizing our proprietary know-how and integrated scientific and drug development capabilities, we have identified multiple drug candidates that modulate ion channels. Our four most advanced programs are: senicapoc for sickle cell disease. We initiated a pivotal Phase III clinical trial of senicapoc in the first quarter of 2005. In June 2004, we entered into collaboration and copromotion agreements with McNeil relating to the development and commercialization of senicapoc; lead compounds for epilepsy and neuropathic pain, for which we are conducting preclinical studies; a compound for atrial fibrillation, for which our collaborator Bristol-Myers Squibb is conducting preclinical studies; and lead compounds for dementia, including Alzheimer's disease, for which our collaborator Astellas is conducting preclinical studies, and lead compounds for ADHD, which were derived from the collaboration and for which we are conducting preclinical studies and allegra. ABILIFY ABILIFY DISCMELT ACCOLATE ACCUPRIL 40 mg ACCUPRIL ALL OTHER STRENGTHS ; ACCURETIC ACCUTANE ACEON ACETAMINOPHEN W CODEINE ACETAMINOPHEN W CODEINE LIQ ACIPHEX ACTIMMUNE ACTIQ ACTONEL 35mg ACTONEL ALL OTHER STRENGTHS ; ACTONEL WITH CALCIUM ACTOPLUS MET ACTOS ACUFLEX ADALAT CC ADDERALL 20mg ADDERALL ALL OTHER STRENGTHS ; ADDERALL XR ADVAIR DISKUS ADVAIR HFA ADVICOR AEROBID AEROBID-M ALBUTEROL 90MCG ALBUTEROL SULFATE HFA ALCET ALFERON N ALLEGRA SUSP ALLEGRA 180 mg ALLEGRA 30 mg, 60 mg ALLEGRA-D 12 HR ALLEGRA-D 24 HR ALORA 30 tabs 30 days 30 tabs 30 days 60 tabs 30 days 60 tabs 30 days 30 tabs 30 days 30 tabs 30 days 60 caps 30 days 30 tabs 30 days 390 tabs 30 days 5010 ml 30 days 30 tabs 30 days 12 vials 30 days 120 lollipops 30 days 4 tabs 30 days 30 tabs 30 days 28 tabs 30 days 90 tabs 30 days 30 tabs 30 days 360 tabs 30 days 30 tabs 30 days 90 tabs 30 days 60 tabs 30 days 60 caps 30 days 1 disk 30 days 1 inhaler 30 days 60 tabs 30 days 3 inhalers 30 days 3 inhalers 30 days 2 inhalers 30 days 2 inhalers 30 days 240 tabs 30 days 4 vials 30 days 300 ml 30 days 30 tabs 30 days 60 tabs 30 days 60 tabs 30 days 30 tabs 30 days 8 patches 30 days ALTACE ALTOPREV ALUPENT INHALER AMBIEN AMBIEN CR AMERGE AMEVIVE AMLODIPINE-BENAZEPRIL AMNESTEEM AMPHETAMINE SALTS 20 mg AMPHETAMINE SALTS ALL OTHER STRENGTH ; ANA-KIT ANDRODERM 2.5mg 24HR PT24 ANDRODERM 5mg 24HR PT24 ANDROGEL GEL MD PMP ANDROGEL GEL PACK 1% 25mg ; ANDROGEL GEL PACK 1% 50mg ; ANTARA ANZEMET APOKYN ARALAST 1, 000 mg ARALAST 500 mg ARANESP ARANESP 150 MCB .75 ARAVA 10 mg, 20 mg ARAVA 100 mg ARICEPT ARICEPT ODT ARIMIDEX ARIXTRA ASACOL ASTELIN ATACAND ATACAND HCT ATROVENT ATROVENT HFA AVALIDE AVANDAMET 30 caps 30 days 30 tabs 30 days 4 inhalers 30 days 30 tabs 30 days 30 tabs 30 days 9 tabs 30 days 4 vials 30 days 30 caps 30 days 60 caps 30 days 90 tabs 30 days 60 tabs 30 days 1 kit copayment 90 patches 30 days 30 patches 30 days 2 gel pumps 30 days 120 packets 30 days 60 packets 30 days 30 caps 30 days 12 tabs 30 days 60 cartridges 30 days 24 vials 30 days 48 vials 30 days 4 vials-syringes 30 days 3 vials 30 days 30 tabs 30 days 3 tabs 30 days 30 tabs 30 days 30 tabs 30 days 30 tabs 30 days 10 syringes 30 days 360 tabs 30 days 1 nasal spray 30 days 30 tabs 30 days 30 tabs 30 days 1 nasal spray 30 days 2 inhalers 30 days 30 tabs 30 days 60 tabs 30 days. Erythematosus. Sera from all 10 patients were negative for antibodies to nuclear antigens and had normal levels of C3 and C4 at presentation and at the time of vasculitic transformation. In addition there was no clinical evidence of systemic lupus erythematosus in these 10 patients. The nephrotic syndrome was defined as the presence of oedema, together with an urinary protein excretion 3.5 g day and a serum albumin 30 g l. Renal insuciency was defined as a plasma creatinine 150 mmol l. Hypertension was defined as a blood pressure 140 90 mmHg if 65 years of age or 145 95 mmHg if 65 of age, or using antihypertensive medication and aristocort.

Scarlatti G Paediatric HIV infection. Lancet, 1996, 348 9031 ; : 863-868. For diagnosis of HIV- 1 infection in children, it is no longer necessary to wait for clinical signs of AIDS to appear or for the child to reach 18 months of age, when conventional serological rests can be used. With appropriate techniques, early diagnosis is now possible by 3 months of age. Multivariate analysis of virological and immunological variables soon after birch should provide a reliable picture of markers of disease progression. The evidence of abundant virus replication at an early age has important implications for clinical management, and for initiation of medical therapies. The discovery of a class of HIV coreceptors gives a new insight into virus-host interactions; control of viral load and cell tropism via different use of co-receptors has become important to the understanding of disease progression and transmission. Denizens. Most importantly, "a hundred beasts" will be driven from their homes; the material extermination and management of animals is critical to the efficient extraction of resources from the forests, and the extermination and control of animality is critical to the project of fashioning appropriate humanity. Although Kipling was familiar with accounts of real feral children, Mowgli is modelled after the mythical heroic wild children of Europe; unlike feral children in India and elsewhere, Mowgli has language, walks on two legs, and knows not only that he is human and superior to animals but also that Gisborne is British and superior to him. His distance from the native human in conjunction with his romanticised animality serves to establish him in Gisborne's eyes as properly and desirably human. Mowgli's animality not only does not disrupt the animal-human hierarchy it also serves precisely to reinforce it. Moreover, like Gisborne's power over the region as a whole, Mowgli's power over the forest comes from his intimate knowledge of the ways of its inhabitants, knowledge that both characters use unself-consciously in colonial service. Mowgli, unlike feral children, knows human ways but prefers his jungle way. Like Kim who chooses when to be native and when sahib and to what end, Mowgli, too, chooses the extent and effect of his animality and his humanity. This ability to know and control both his animality and his humanity establishes Mowgli as preeminently human and beconase.
DESCRIPTION ISTALOL timolol maleate ophthalmic solution ; 0.5% is a non-selective beta-adrenergic receptor blocking agent. Its chemical name is - ; -1- tert-butylamino ; 3- [ 4-morpholino-1, 2, 5-thiadiazol-3-yl ; oxy]-2propanol maleate 1: ; salt ; . Timolol maleate possesses an asymmetric carbon atom in its structure and is provided as the levo-isomer. The optical rotation of timolol maleate is: [] 25 in 1.0N HCl C 5% ; -12.2 -11.7 to -12.5 ; 405 nm The same adverse reactions found with systemic administration of beta-adrenergic blocking agents may occur with topical administration. For example, severe respiratory reactions and cardiac reactions, including death due to bronchospasm in patients with asthma, and rarely death in association with cardiac failure, have been reported following systemic or ophthalmic administration of timolol maleate see CONTRAINDICATIONS ; . Cardiac Failure Sympathetic stimulation may be essential for support of the circulation in individuals with diminished myocardial contractility, and its inhibition of beta-adrenergic receptor blockade may precipitate more severe failure. In Patients Without a History of Cardiac Failure continued depression of the myocardium with beta-blocking agents over a period of time can, in some cases, lead to cardiac failure. At the first sign or symptom of cardiac failure, ISTALOL should be discontinued. Obstructive Pulmonary Disease Patients with chronic obstructive pulmonary disease e.g., chronic bronchitis, emphysema ; of mild or moderate severity, bronchospastic disease, or a history of bronchospastic disease other than bronchial asthma or a history of bronchial asthma, in which ISTALOL is contraindicated [see CONTRAINDICATIONS] ; should, in general, not receive beta-blockers, including ISTALOL. Major Surgery The necessity or desirability of withdrawal of beta-adrenergic blocking agents prior to major surgery is controversial. Beta-adrenergic receptor blockade impairs the ability of the heart to respond to beta-adrenergically mediated reflex stimuli. This may augment the risk of general anesthesia in surgical procedures. Some patients receiving beta-adrenergic receptor blocking agents have experienced protracted severe hypotension during anesthesia. Difficulty in restarting and maintaining the heartbeat has also been reported. For these reasons, in patients undergoing elective surgery, some authorities recommend gradual withdrawal of betaadrenergic receptor blocking agents. If necessary during surgery, the effects of beta-adrenergic blocking agents may be reversed by sufficient doses of adrenergic agonists. Diabetes Mellitus Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous hypoglycemia or to diabetic patients especially those with labile diabetes ; who are receiving insulin or oral hypoglycemic agents. Beta-adrenergic receptor blocking agents may mask the signs and symptoms of acute hypoglycemia. Thyrotoxicosis Beta-adrenergic blocking agents may mask certain clinical signs e.g., tachycardia ; of hyperthyroidism. Patients suspected of developing thyrotoxicosis should be managed carefully to avoid abrupt withdrawal of beta-adrenergic blocking agents that might precipitate a thyroid storm. PRECAUTIONS General Because of potential effects of beta-adrenergic blocking agents on blood pressure and pulse, these agents should be used with caution in patients with cerebrovascular insufficiency. If signs or symptoms suggesting reduced cerebral blood flow develop following initiation of therapy with ISTALOL, alternative therapy should be considered. There have been reports of bacterial keratitis associated with the use of multiple dose containers of topical ophthalmic products. These containers had been inadvertently contaminated by patients who, in most cases, had a concurrent corneal disease or a disruption of the ocular epithelial surface. See PRECAUTIONS, Information for Patients. ; Choroidal detachment after filtration procedures has been reported with the administration of aqueous suppressant therapy e.g. timolol ; . Angle-closure glaucoma: In patients with angle-closure glaucoma, the immediate objective of treatment is to reopen the angle. This requires constricting the pupil. Timolol maleate has little or no effect on the pupil. ISTALOL should not be used alone in the treatment of angle-closure glaucoma. Anaphylaxis: While taking beta-blockers, patients with a history of atopy or a history of severe anaphylactic reactions to a variety of allergens may be more reactive to repeated accidental, diagnostic, or therapeutic challenge with such allergens. Such patients may be unresponsive to the usual doses of epinephrine used to treat anaphylactic reactions. Muscle Weakness: Beta-adrenergic blockade has been reported to potentiate muscle weakness consistent with certain myasthenic symptoms e.g., diplopia, ptosis, and generalized weakness ; .Timolol has been reported rarely to increase muscle weakness in some patients with myasthenia gravis or myasthenic symptoms. Information for Patients Patients should be instructed to avoid allowing the tip of the dispensing container to contact the eye or surrounding structures. Patients should also be instructed that ocular solutions, if handled improperly or if the tip of the dispensing container contacts the eye or surrounding structures, can become contaminated by common bacteria known to cause ocular infections. Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions. See PRECAUTIONS, General. ; Patients should also be advised that if they have ocular surgery or develop an intercurrent ocular condition e.g., trauma or infection ; , they should immediately seek their physician's advice concerning the continued use of the present multidose container. Patients with bronchial asthma, a history of bronchial asthma, severe chronic obstructive pulmonary disease, sinus bradycardia, second or third degree atrioventricular block, or cardiac failure should be advised not to take this product. See CONTRAINDICATIONS. ; Patients should be advised that ISTALOL contains benzalkonium chloride which may be absorbed by soft.

Meda decided to contribute SEK 35 million over a five-year period to Karolinska Institutet's research on inflammatory diseases. Meda is thus helping to further research in this field, which is one of the company's priority therapeutic areas. KEY EVENTS AFTER THE BALANCE SHEET DATE MEDA AND APOTEX ENTERED INTO A SETTLEMENT AGREEMENT ABOUT ASTELIN IN THE US and medrol. ABILIFY excluding solution ; ACCU-CHEK ACTIVE KIT ACCU-CHEK ACTIVE test strips ACCU-CHEK ADVANTAGE KIT ACCU-CHEK ADVANTAGE test strips ACCU-CHEK AVIVA KIT ACCU-CHEK AVIVA test strips ACCU-CHEK COMFORT CURVE test strips ACCU-CHEK COMPACT KIT ACCU-CHEK COMPACT test strips ACCU-CHEK COMPLETE KIT acetaminophen w codeine acetazolamide acetylcysteine ACTONEL, with calcium acyclovir ADDERALL XR * ADVAIR DISKUS ADVICOR AGGRENOX albuterol ALLEGRA * ALLEGRA-D * excluding 24 hours ; ALOMIDE ALORA ALPHAGAN P ALTACE aluminum chloride amantadine AMBIEN aminophylline amitriptyline ammonium lactate amox tr potassium clavulanate amoxicillin ANALPRAM-HC * 1% cream, 2.5% lotion ; ANDRODERM ANDROGEL antipyrine w benzocaine apri aranelle ARANESP [INJ] ARICEPT ASACOL ASTELIN atenolol, -chlorthalidone ATROVENT inh, HFA AUGMENTIN XR AVANDAMET AVANDIA AVELOX aviane AVODART azathioprine azithromycin CONCERTA * COREG COSOPT COZAAR CREON [G] CRESTOR cromolyn sodium cryselle cyclobenzaprine hcl cyclosporine, modified CYMBALTA [SNRI].
HIP FRACTURES IN CORK CITY AND COUNTY 1994-2003 : OVERALL INCIDENCE STABLE BUT DEMOGRAPHICS CHANGING. B. Whelan1, I. Brennan2, E. Falvey1, B.J. Plant1, M. Dolan2, M.G. Molloy1 1 Department of Rheumatology and Sports Medicine, CUH, Wilton Cork and 2 Department of Orthopaedics, CUH, Wilton, Cork Introduction: Hip fracture is the most serious complication of osteoporosis. Incidence rates can vary significantly between and within countries1 and there are no up to date data for the Cork population. Aim: This study was undertaken to establish the incidence of hip fracture in an Irish population and to analyse it's changing demographics in the years 1994-2003. Methods: Data was collected from the HIPE database for Cork University Hospital CUH ; . This is the only orthopaedic trauma centre for Cork city and county. Using census data the population statistics for this region were calculated for each year from 1994-2003. Results: During the study period there were 3616 Hip fractures 24.8% Men, 75.2% Women ; out of 1, 105, 994 subject years in the over 50 age group. Fracture incidence in women 172 100, 000 pt yrs ; was significantly greater than men 22.4 100, 000 pt yrs ; p 0.0001 ; . An increase in fracture incidence with increasing age was noted in both sexes see table ; . Between 1994 and 2003 fracture incidence increased in the over 80 year olds in both sexes and decreased in 75-79 year females and 70-74 year old males p 0.001.

Flurodeoxyglucose F-18 FDG, diagnostic, per study dose, up to 45 mCi per A9552 A9578 A9577 A9579 A9576 A9556 A9507 A9542 A9571 A9570 A9547 A9548 A9572 A9516 A9509 A9532 A9554 A9508 A9524 A9529 A9531 A9517 A9528 A9530 A9544 A9545 Q9965 Q9966 Q9967 Q9951 A9535 A9526 Q9957 A9699 A4641 A9555 A9605 J2805 A9563 A9600 A9700 A9504 study dose up to 45 mCi Gadobenate Dimaglumine multihance multipack ; per ml Gadobenate Dimeglumine multihance ; per ml Gadolinium-based magnetic response contrast agent, not otherwise $ $ $ 648.96 2.68 2.85 manual 163.80 55.12 manual 2, 607.19 22, manual $ 4.27 manual $ 61.89 manual manual 30, 875.00 1, manual manual 1 2008 Y Y Y and buy allegra.

Free Astelin